Outcome measures | Group I (NP) (n = 34 lower limbs obtained from 22 patients) mean ± SD | Group II (CS) (n = 33 lower limbs obtained from 21 patients) mean ± SD | Test of significance§ | P |
---|---|---|---|---|
WOMAC pain subscale | ||||
 Preinjection assessment | 13.18 ± 3.78 | 10.95 ± 4.26 | 1.816 | 0.077 |
 Postinjection assessment | 2.31 ± 2.58 | 1.71 ± 2.02 | 0.849 | 0.401 |
 Test of significance†| 14.040 | 10.862 |  |  |
 P | ≤ 0.0001* | ≤ 0.0001* |  |  |
WOMAC stiffness subscale | ||||
 Preinjection assessment | 1.36 ± 0.78 | 1.28 ± 0.71 | 0.338 | 0.737 |
 Postinjection assessment | 0.22 ± 0.42 | 0.19 ± 0.51 | 0.256 | 0.799 |
 Test of significance†| 6.884 | 6.532 |  |  |
 P | ≤ 0.0001* | ≤ 0.0001* |  |  |
WOMAC function subscale | ||||
 Preinjection assessment | 25.13 ± 7.26 | 21.00 ± 7.94 | 1.783 | 0.082 |
 Postinjection assessment | 4.68 ± 5.83 | 3.14 ± 4.04 | 1.001 | 0.323 |
 Test of significance†| 13.838 | 11.971 |  |  |
 P | ≤ 0.0001* | ≤ 0.0001* |  |  |
WOMAC total | ||||
 Preinjection assessment | 39.68 ± 10.20 | 33.23 ± 11.75 | 1.922 | 0.062 |
 Postinjection assessment | 7.09 ± 8.46 | 5.42 ± 7.54 | 0.679 | 0.501 |
 Test of significance†| 16.048 | 11.387 |  |  |
 P | ≤0.0001* | ≤0.0001* |  |  |
Overall AB pain severity (VAS) | ||||
 Preinjection assessment | 8.76 ± 1.34 | 8.78 ± 1.45 | − 0.068 | 0.946 |
 Postinjection assessment | 1.52 ± 1.82 | 0.96 ± 1.49 | 1.371 | 0.175 |
 Test of significance†| 20.773 | 23.105 |  |  |
 P | ≤ 0.0001* | ≤ 0.0001* |  |  |
Patient’s global assessment of AB severity (VAS) | ||||
 Preinjection assessment | 8.10 ± 1.38 | 8.54 ± 1.37 | − 1.316 | 0.193 |
 Postinjection assessment | 1.00 ± 1.37 | 0.81 ± 1.23 | 0.570 | 0.571 |
 Test of significance†| 22.101 | 29.084 |  |  |
 P | ≤ 0.0001* | ≤ 0.0001* |  |  |
Tenderness at the anserine bursa region | ||||
 Preinjection assessment‡ | 34 (100) | 33 (100) | NA | NA |
 Postinjection assessment‡ | 11 (32.4) | 6 (18.2) | 1.776|| | 0.262 |